causaLens launches the first causal AI platform
22.9.2020 16:00:00 EEST | Business Wire | Press release
causaLens , a deep-tech company predicting and optimising the global economy, has released the World’s first causal Artificial Intelligence (causal AI) enterprise platform. Businesses no longer have to rely on curve-fitting machine learning platforms unable to handle the complexity of today's world. They are invited to join the real AI revolution with a platform that understands cause and effect.
The causaLens platform defines a new category of machine intelligence. Its next generation AI engine harnesses an understanding of cause and effect relationships to directly optimise business KPIs.
“Businesses investing in the current form of machine learning (ML), including AutoML, have just been paying to automate a process that fits curves to data without an understanding of the real world. They are effectively driving forward by looking in the rear-view mirror,” explains causaLens CEO Darko Matovski. “Our platform takes a radically different approach. Causal AI teaches machines to understand cause and effect, a necessary step to developing true AI. This allows our platform to autonomously operate at a new level of abstraction that explains to businesses what actions they need to take to achieve their objectives.”
causaLens has a track record of breaking new ground, having pioneered automated machine learning (AutoML) for time series data. The causal AI platform retains the advantages of comprehensive automation, allowing thousands of data sets to be cleaned, sorted and monitored at the same time. However, it combines it with causal models and insights that are truly explainable - traditionally the sole province of domain experts. Unique human knowledge is harnessed through intuitive interfaces for human-machine partnerships.
Since its inception in 2017, causaLens has worked with a range of corporates across multiple industries. Customers include some of the world’s largest Asset Managers, Hedge Funds, Tier-1 Investment Banks, Transportation and Logistics companies, and Energy and Commodity traders.
Masami Johnstone, Head of Information Services at CLS, whose products help clients navigate the changing Foreign Exchange marketplace, said: "The causaLens platform has enabled us to discover additional value in our data. Their causal AI technology autonomously finds valuable signals in huge datasets and has helped us to understand relationships between our data and other datasets.”
Today’s world is changing faster than ever before. Current state of the art ML barely scratches the surface of what machines can do. Causal AI is the next huge step forward.
Demonstrations of the product can be requested via causaLens.com.
causaLens
causaLens is pioneering Causal AI, a new category of intelligent machines that understand cause and effect - a major step towards true AI. Its enterprise platform is used to transform leading businesses in Finance, IoT, Energy, Telecommunications and others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005020/en/
Contact information
Press:
Darko Matovski,
CEO and co-founder
E: darko@causalens.com
www.causaLens.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
